The global Urinary Tract Infection (UTI) therapeutics market is undergoing a structural shift. Major players like Zambon (31% share) and Hunan Huana Pharmaceuticals (24% share) are scaling production to meet this high-margin demand. This has led to a 30-40% volume reduction in these drugs, forcing a market pivot toward Nitrofurans and newer Beta-lactam combinations. Why Choose FMI: Empowering Decisions that Drive Real-World Outcomes: https://www.futuremarketinsights.com/why-fmiAbout Future Market Insights (FMI)Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.